Efficacy and safety of relacorilant for the treatment of patients with Cushing's syndrome (GRACE): a multicentre, phase 3, double-blind, placebo-controlled, randomised-withdrawal study Patients treated with relacorilant were more likely to maintain hypertension control compared with patients treated with placebo. The findings support consideration of relacorilant as a therapeutic op...

Patients with endogenous #hypercortisolism of various causes given #relacorilant during the randomised-withdrawal phase were 5·9 times more likely to maintain #hypertension response compared with those who received placebo thelancet.com/journals/lan...
#Cushing's syndrome

#MedSky #EndoSky

Corcept Therapeutics Faces Securities Class Action After Major Failures with FDA and Patent Lawsuit Corcept Therapeutics is facing a class action lawsuit after an FDA rejection and a significant patent loss prompted involvement from Hagens Berman. Investors must act by April 21.

Corcept Therapeutics Faces Securities Class Action After Major Failures with FDA and Patent Lawsuit #United_States #San_Francisco #Hagens_Berman #Corcept_Therapeutics #Relacorilant

Corcept Therapeutics Faces Class Action Lawsuit Over Misleading Drug Approval Claims Corcept Therapeutics is facing a securities class action lawsuit for allegedly misleading investors about the approval of its drug, relacorilant. Key deadlines are approaching.

Corcept Therapeutics Faces Class Action Lawsuit Over Misleading Drug Approval Claims #United_States #San_Francisco #Hagens_Berman #Corcept_Therapeutics #Relacorilant

Corcept Therapeutics Faces Class Action Lawsuit Amid FDA Warnings Affecting Stock Value Hagens Berman is alerting investors about a class action against Corcept Therapeutics due to alleged FDA warnings and stock plummet. Key deadlines await!

Corcept Therapeutics Faces Class Action Lawsuit Amid FDA Warnings Affecting Stock Value #Hagens_Berman #Corcept_Therapeutics #Relacorilant

Corcept Therapeutics Faces Scrutiny Amid FDA Warning on New Drug Application Corcept Therapeutics is under investigation following FDA warnings regarding its drug application. Shareholder concerns are escalating as stock prices plummet.

Corcept Therapeutics Faces Scrutiny Amid FDA Warning on New Drug Application #United_States #San_Francisco #Corcept_Therapeutics #FDA_Warning #Relacorilant

Corcept Therapeutics’ relacorilant plus nab-paclitaxel shows positive results in ovarian cancer - PharmaTimes Ovarian cancer is the fifth leading cause of deaths from cancer in women

#oncology #womenshealth #CorceptTherapeutics #relacorilant #ovariancancer #cancerinwomen #cortisolmodulatingmedications #platinumresistantovariancancer #ROSELLAtrial #gynaecologicalcancerresearch #glucocorticoidreceptor #cortisolmodulatingtreatments
zurl.co/JWBM3

Ovarian cancer data restores faith in Corcept's relacorilant After Corcept's setback with relacorilant in Cushing syndrome last month, the company has bounced back with strong survival data in ovarian cancer.

After #CorceptTherapeutics setback with #relacorilant in Cushing syndrome last month, the company has bounced back with strong data in #ovariancancer, firming its share price.

pharmaphorum.com/news/ovarian...

Corcept Therapeutics Shares Plummet 50% Following FDA Response on Relacorilant Corcept Therapeutics experiences a staggering 50% drop in shares after receiving an FDA Complete Response Letter for relacorilant, raising investor concerns.

Corcept Therapeutics Shares Plummet 50% Following FDA Response on Relacorilant #USA #San_Francisco #FDA_Response #Corcept_Therapeutics #Relacorilant

Corcept Therapeutics' Share Prices Plummet Following FDA Response on Relacorilant Treatment Corcept Therapeutics faced a major setback after the FDA issued a Complete Response Letter, leading to a 50% drop in share prices, prompting investor scrutiny.

Corcept Therapeutics' Share Prices Plummet Following FDA Response on Relacorilant Treatment #United_States #San_Francisco #FDA #Corcept_Therapeutics #Relacorilant

FDA declines to approve Corcept's rare disorder drug As the celebrations for the end of 2025 gathered pace, the FDA delivered a year-end blow to Corcept by turning down its new Cushing's drug.

As the celebrations for the end of 2025 gathered pace, the FDA delivered a year-end blow to #CorceptTherapeutics with a decision not to approve #relacorilant, a drug for a rare #hormonaldisorder that causes #highbloodpressure.